EE04552B1 - Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid - Google Patents

Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid

Info

Publication number
EE04552B1
EE04552B1 EEP200100126A EEP200100126A EE04552B1 EE 04552 B1 EE04552 B1 EE 04552B1 EE P200100126 A EEP200100126 A EE P200100126A EE P200100126 A EEP200100126 A EE P200100126A EE 04552 B1 EE04552 B1 EE 04552B1
Authority
EE
Estonia
Prior art keywords
processes
alendronate sodium
pharmaceutical compositions
preparation
sodium salt
Prior art date
Application number
EEP200100126A
Other languages
English (en)
Inventor
Finkelstein Nina
Lidor-Hadas Ramy
Aronhime Judith
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of EE200100126A publication Critical patent/EE200100126A/et
Publication of EE04552B1 publication Critical patent/EE04552B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EEP200100126A 1998-08-27 1999-08-27 Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid EE04552B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
EE200100126A EE200100126A (et) 2002-06-17
EE04552B1 true EE04552B1 (et) 2005-10-17

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100126A EE04552B1 (et) 1998-08-27 1999-08-27 Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid

Country Status (30)

Country Link
US (2) US6281381B1 (et)
EP (1) EP1107974B1 (et)
JP (2) JP2002523514A (et)
KR (2) KR20010079701A (et)
AT (1) ATE334993T1 (et)
AU (1) AU5698899A (et)
BG (1) BG65329B1 (et)
BR (1) BR9913472A (et)
CA (1) CA2341459A1 (et)
CZ (1) CZ2001629A3 (et)
DE (1) DE69932620T2 (et)
DK (1) DK1107974T3 (et)
EA (1) EA002739B1 (et)
EE (1) EE04552B1 (et)
ES (1) ES2270613T3 (et)
HR (1) HRP20010129A2 (et)
HU (1) HUP0203078A3 (et)
IL (1) IL141423A (et)
IS (1) IS5864A (et)
LT (1) LT4888B (et)
LV (1) LV12720B (et)
NO (1) NO20010957L (et)
NZ (1) NZ510682A (et)
PL (1) PL346347A1 (et)
PT (1) PT1107974E (et)
RO (1) RO122854B1 (et)
SI (1) SI20581B (et)
SK (1) SK2482001A3 (et)
WO (1) WO2000012517A1 (et)
YU (1) YU14701A (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
WO2003057136A2 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
PT1753395E (pt) 2004-05-24 2010-10-21 Warner Chilcott Co Llc Forma entérica sólida de dosagem oral de um bisfosfonato contendo um agente quelante
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
ATE440888T1 (de) * 2004-10-29 2009-09-15 Sandoz Ag Verfahren zur herstellung von glatiramer
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
BRPI0717394A2 (pt) * 2006-10-27 2013-10-15 Signal Pharm Llc Forma cristalina, composição farmacêutica, forma de dosagem unitária única, método para tratar ou prevenir uma doença ou condição, e, processo para preparar um composto
JP5244608B2 (ja) * 2006-11-22 2013-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 二糖類化合物のナトリウム塩及びその製造方法並びにその使用
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
US8629178B2 (en) * 2009-11-03 2014-01-14 Li Liu Sodium tanshinone IIA sulfonate hydrate and preparation method and use thereof
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
AU6148396A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Disodium alendronate formulations
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten

Also Published As

Publication number Publication date
US6696601B2 (en) 2004-02-24
DE69932620D1 (de) 2006-09-14
NZ510682A (en) 2003-09-26
EA002739B1 (ru) 2002-08-29
EP1107974B1 (en) 2006-08-02
BG65329B1 (bg) 2008-02-29
EP1107974A1 (en) 2001-06-20
EA200100184A1 (ru) 2001-10-22
SI20581A (sl) 2001-12-31
ES2270613T3 (es) 2007-04-01
YU14701A (sh) 2003-01-31
SK2482001A3 (en) 2002-01-07
CZ2001629A3 (cs) 2001-08-15
IS5864A (is) 2001-02-26
HUP0203078A2 (hu) 2003-01-28
AU5698899A (en) 2000-03-21
WO2000012517A9 (en) 2000-07-13
RO122854B1 (ro) 2010-03-30
US6281381B1 (en) 2001-08-28
EP1107974A4 (en) 2001-09-26
JP2002523514A (ja) 2002-07-30
US20030065214A1 (en) 2003-04-03
LV12720A (lv) 2001-09-20
HUP0203078A3 (en) 2005-01-28
BR9913472A (pt) 2002-03-05
NO20010957D0 (no) 2001-02-26
NO20010957L (no) 2001-04-26
LT4888B (lt) 2002-02-25
PT1107974E (pt) 2006-10-31
HRP20010129A2 (en) 2005-04-30
KR20070034132A (ko) 2007-03-27
BG105292A (en) 2001-12-29
JP2009143955A (ja) 2009-07-02
LV12720B (en) 2002-02-20
CA2341459A1 (en) 2000-03-09
DK1107974T3 (da) 2006-10-30
SI20581B (sl) 2008-06-30
IL141423A (en) 2005-09-25
ATE334993T1 (de) 2006-08-15
EE200100126A (et) 2002-06-17
WO2000012517A1 (en) 2000-03-09
KR20010079701A (ko) 2001-08-22
PL346347A1 (en) 2002-02-11
LT2001016A (en) 2001-10-25
IL141423A0 (en) 2002-03-10
DE69932620T2 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
EE04552B1 (et) Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid
MY119970A (en) Method of fertilizing an avian egg in the shell
AU7642001A (en) Novel $G(Y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
MY119968A (en) Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
HU0102813D0 (en) New betha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it
ZA200210092B (en) alpha crystalline form of perindopril tert-butylamine salt.
HUP0401141A3 (en) Crystalline forms of fluvastatin sodium, process for their preparation and pharmaceutical compositions containing them
HUP0402391A3 (en) Crystalline sodium salt of telmisartan, process for its production and pharmaceutical compositions containing it
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
EE04778B1 (et) Hargnenud ahelaga asendatud 3-amino-1-fenüül-1H-[1,2,4]triasooli aminoderivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
CA2431515A1 (en) Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof
NO20002962D0 (no) FremgangsmÕte for fremstilling av fludarabinfosfatlium-, - natrium-, -kalium-, -kalsium- og -magnesiumsalter, fremgangsmÕte for rensing av fludarabinfosfat, og fludarabinfosfat som er minst 99,5% rent
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
HK1034715A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
HU0102815D0 (en) New alpha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it
ZA200101451B (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof.

Legal Events

Date Code Title Description
HD1A Correction of address
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090827